Royce & Associates LP Has $2,487,000 Position in Meridian Bioscience Inc. (VIVO)

Royce & Associates LP continued to hold its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,894 shares of the company’s stock at the end of the 2nd quarter. Royce & Associates LP owned 0.37% of Meridian Bioscience worth $2,487,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Karp Capital Management Corp acquired a new stake in Meridian Bioscience during the 1st quarter valued at $507,000. Highbridge Capital Management LLC acquired a new stake in Meridian Bioscience during the 1st quarter valued at $1,279,000. Wells Fargo & Company MN raised its stake in Meridian Bioscience by 50.2% during the 1st quarter. Wells Fargo & Company MN now owns 767,606 shares of the company’s stock valued at $10,593,000 after purchasing an additional 256,571 shares during the period. Citadel Advisors LLC raised its stake in Meridian Bioscience by 142.8% during the 1st quarter. Citadel Advisors LLC now owns 166,326 shares of the company’s stock valued at $2,295,000 after purchasing an additional 97,822 shares during the period. Finally, Teachers Advisors LLC raised its stake in Meridian Bioscience by 2.7% during the 4th quarter. Teachers Advisors LLC now owns 69,137 shares of the company’s stock valued at $1,224,000 after purchasing an additional 1,828 shares during the period. 87.27% of the stock is currently owned by institutional investors.

VIVO has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Three research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Meridian Bioscience presently has an average rating of “Hold” and a consensus price target of $14.75.

In related news, Chairman John A. Kraeutler acquired 7,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the acquisition, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.30% of the company’s stock.

Shares of Meridian Bioscience Inc. (VIVO) opened at 14.05 on Tuesday. The firm has a market capitalization of $592.95 million, a P/E ratio of 28.10 and a beta of 0.86. Meridian Bioscience Inc. has a 52 week low of $10.75 and a 52 week high of $19.85. The firm’s 50-day moving average is $13.90 and its 200 day moving average is $14.14.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The business had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period last year, the business posted $0.21 earnings per share. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. Equities research analysts forecast that Meridian Bioscience Inc. will post $0.67 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 17th. Investors of record on Monday, August 7th were issued a dividend of $0.125 per share. The ex-dividend date was Thursday, August 3rd. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.56%. Meridian Bioscience’s payout ratio is 98.04%.

WARNING: “Royce & Associates LP Has $2,487,000 Position in Meridian Bioscience Inc. (VIVO)” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/09/12/royce-associates-lp-has-2487000-position-in-meridian-bioscience-inc-vivo.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply